Coronary Artery BypassCONTINUUM LINTNCT06602336
A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection to Standard Measurements of Lactate in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery and/or Valve Replacement.
A study testing Continuous Lactate Monitoring Device in people with Coronary Artery Bypass and Coronary Artery Bypass Graft, run by Queen Mary University of London at 1 site in United Kingdom.
Trial summary
The main goal of this study is to see if a wearable device can reliably track changes in lactate levels in the body. We\'ll compare the device\'s readings to standard blood tests to ensure accuracy. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Coronary Artery Bypass, Coronary Artery Bypass Graft, Coronary Artery Bypass Graft Surgery (CABG)
- What is being tested?
- Continuous Lactate Monitoring Device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 61 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 20 May 2025to 27 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able and willing to give informed consent
- ≥18 to ≤ 90 years old
- Successful surgery as defined by the below criteria (which will be recorded in the eCRF):
- Operative Success: The successful completion of coronary artery bypass grafting (CABG) and/or valve insertion with grafts and/or valves
- Absence of the following complications:
- Significant bleeding requiring reoperation
- Evidence of major life-changing stroke
Who cannot join
- Previous coronary artery bypass grafting
- Recent acute coronary syndrome (within 4 weeks of planned consent date)
- Heart failure with EF less than 35% (from TTE or CT from past 6 months - if both available lower value will be used).
- Chronic severe renal failure (estimated eGFR less than 30 mL/min/1.73m2 by the MDRD formula recorded at time of consent)
- Severe anaemia (Hb less than 10 recorded at time of consent)
- Known or suspected allergies to medical grade silicone adhesives
Show all 15Show fewer
- Pre-existing skin condition on the upper arm where the device would be applied, including recent burns/ scalds, open wounds or clinically significant skin lesions.
- Patients with implanted medical devices such as pacemakers or other CLMs
- Severe liver cirrhosis (≥ stage III)
- Lymphoedema or pitting oedema at the time of consent
- Pregnancy
- History of ongoing malignant disease
- Hypoalbuminaemia (less than 35 g/L recorded at time of consent)
- Those lacking capacity to consent or are deemed vulnerable adults
- Unable to speak English
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection (as Measured by Change in Current) to Standard Measurements of Change in Venous and Arterial Lactate in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery and/or Valve Replacement.
The main goal of this study is to see if a wearable device can reliably track changes in lactate levels in the body. We\'ll compare the device\'s readings to standard blood tests to ensure accuracy. If successful, this device could reduce the need for frequent blood tests during surgery recovery, making patients more comfortable. It might also be useful in emergency rooms for quick diagnoses, especially for patients with chest pain.
This study will take place at Barts Hospital with patients having planned coronary artery bypass graft (CABG) and/or replacement valve surgery. Participants will wear the sensors on their upper arm, during which the sensors will continuously measure lactate levels. Participants will also have hourly blood samples taken.
In the future, the data from this new device will be used to train computer algorithms to provide quick responses that help manage a patient\'s condition, improving future medical care and technology.
Read the detailed description
Summary of the study design and methodology
The research nurse or doctor will meet with the patient to explain the study and check the following:
Pre-screening: The research nurse, who may also be part of the patient\'s direct care team, will look at the records for patients who are attending St Bartholomew's hospital for cardiac surgery for grafts and/or valve replacement.
Informed Consent: If the patient is eligible, and would like to take part in the study, the research nurse or doctor will ask the patient to sign a consent form indicating their willingness to participate in the study.
Screening: The research nurse or doctor will collect demographic information from the patient and ensure the patient meets the study's inclusion and exclusion criteria.
Sensor Application: Up to 5 days pre-surgery, the research nurse will place two lactate sensors on the patient's arm. The sensor has a 24 hour warm-up period prior to continuously measuring the patient's lactate levels.
Pre-Surgery Admission: The research nurse will gather details about the patient's medical history and current medications. The patient will have their blood pressure, heart rate, respiratory rate, weight, and height measured, and an ECG performed. Baseline blood samples will be collected as per the standard of care pre-CABG and/or valve surgery.
CABG and/or replacement valve surgery: The patient will then undergo their planned CABG and/or replacement valve surgery as usual.
Blood Sampling: The patient will have hourly blood samples taken through the tubes inserted for their surgery for up to 14 hours to compare with the sensor readings. These samples will include 12 arterial lactate, 12 central venous lactate, and 12 venous troponin samples. Hourly measurements of the patient's blood pressure, heart rate, and respiratory rate will be taken, and any medication changes will be noted.
Sensor Removal: Up to 48 hours post-surgery, the sensors will be removed, and the patient's skin will be checked for any changes, like a rash. The patient will also have their blood pressure, heart rate, and respiratory rate measured, and an ECG performed. Any changes to the patient's medication will be noted.
Follow-Up: The study team will monitor the patient for up to 24 hours after the sensor is removed or until the patient is discharged from the hospital (whichever is earlier). The study team will note any medication changes, measure the patient's blood pressure, heart rate, and respiratory rate, and perform an ECG.
- Conditions
- Coronary Artery Bypass, Coronary Artery Bypass Graft, Coronary Artery Bypass Graft Surgery (CABG), Valve Replacement, Valve Surgery, Cardiovascular
- Being tested
- Continuous Lactate Monitoring Device
- Keywords
- device, cardiovascular, coronary artery bypass surgery, replacement valve surgery, Continuous lactate monitor, CABG, wearable device
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous Lactate Monitoring DeviceDevice
Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
| Study group | Role | What they receive |
|---|---|---|
| Investigational Lactate Device | Experimental | Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device Receives: Device: Continuous Lactate Monitoring Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Continuous lactate sensor measurement compared venous and arterial blood gas lactate measurements.
Correlation coefficients describing the strength of association between the electrical signal from the continuous interstitial fluid lactate measurements and laboratory lactate measurements. Evaluate the change in interstitial fluid lactate measurements via a surrogate output of change in current (nA; using an investigational device by Abbott Diabetes Care Ltd.) to local Radiometer ABL 90 venous and arterial blood gas lactate measurements measured hourly up to 12 samples within a 14-hour period post-elective CABG/valve replacement surgery.
Measured: 14 hours
Continuous lactate sensor measurement compared Troponin-T
Correlation coefficients describing the strength of association between the electrical signal from the continuous interstitial fluid lactate measurements and venous laboratory measurements of high-sensitivity troponin-T. Evaluate the relationship between the current (nA) output of a continuous interstitial fluid lactate monitor (using an investigational device by Abbott Diabetes Care Ltd.) and venous laboratory measurements of high-sensitivity troponin-T measured hourly up to 12 samples within a 14-hour period post-elective CABG/valve replacement surgery.
Measured: 14 hours
Secondary outcomes (4)
Relationship between arterial and venous lactate measurements
Correlation coefficients describing the strength of association between arterial and central venous lactate measurements measured hourly up to 12 samples within a 14- hour period post-elective CABG and/or valve replacement surgery.
Measured: 14 hours
Relationship between arterial and venous lactate and venous troponin measurements
Correlation coefficients describing the strength of association between arterial and central venous lactate and venous troponin measured hourly up to 12 samples within a 14-hour period post-elective CABG and/or valve replacement surgery.
Measured: 14 hours
Functionality of the device for up to 48 hours post-surgery.
Proportion of devices that are able to give a continuous electrical signal for the duration of use post-surgery.
Measured: 48 hours
Evaluate safety of lactate sensor
Number of patients experiencing adverse reactions or serious adverse reactions to the lactate investigational device.
Measured: Up to 8 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start20 May 2025
- Primary completion27 Jan 2026
- Study completion27 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery BypassStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 61 participants (actual)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Prof Anthony Mathur, Study chair, Queen Mary University of London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06602336
- Sponsor's protocol ID
- 346076
- Acronym
- CONTINUUM LINT
- Status last verified
- Jun 2026
- First submitted
- 16 Sep 2024
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection (as Measured by Change in Current) to Standard Measurements of Change in Venous and Arterial Lactate in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery and/or Valve Replacement.
- ClinicalTrials.gov ID
- NCT06602336
- Acronym / sponsor ID
- CONTINUUM LINT / 346076
- Conditions
- Coronary Artery Bypass, Coronary Artery Bypass Graft, Coronary Artery Bypass Graft Surgery (CABG), Valve Replacement, Valve Surgery, Cardiovascular
- Keywords
- device, cardiovascular, coronary artery bypass surgery, replacement valve surgery, Continuous lactate monitor, CABG, wearable device
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 61 participants (actual)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Study start
- 20 May 2025 (actual)
- Primary completion
- 27 Jan 2026 (actual)
- Study completion
- 27 Jan 2027 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main goal of this study is to see if a wearable device can reliably track changes in lactate levels in the body. We\'ll compare the device\'s readings to standard blood tests to ensure accuracy. If successful, this device could reduce the need for frequent blood tests during surgery recovery, making patients more comfortable. It might also be useful in emergency rooms for quick diagnoses, especially for patients with chest pain.
This study will take place at Barts Hospital with patients having planned coronary artery bypass graft (CABG) and/or replacement valve surgery. Participants will wear the sensors on their upper arm, during which the sensors will continuously measure lactate levels. Participants will also have hourly blood samples taken.
In the future, the data from this new device will be used to train computer algorithms to provide quick responses that help manage a patient\'s condition, improving future medical care and technology.
Detailed description
Summary of the study design and methodology
The research nurse or doctor will meet with the patient to explain the study and check the following:
Pre-screening: The research nurse, who may also be part of the patient\'s direct care team, will look at the records for patients who are attending St Bartholomew's hospital for cardiac surgery for grafts and/or valve replacement.
Informed Consent: If the patient is eligible, and would like to take part in the study, the research nurse or doctor will ask the patient to sign a consent form indicating their willingness to participate in the study.
Screening: The research nurse or doctor will collect demographic information from the patient and ensure the patient meets the study's inclusion and exclusion criteria.
Sensor Application: Up to 5 days pre-surgery, the research nurse will place two lactate sensors on the patient's arm. The sensor has a 24 hour warm-up period prior to continuously measuring the patient's lactate levels.
Pre-Surgery Admission: The research nurse will gather details about the patient's medical history and current medications. The patient will have their blood pressure, heart rate, respiratory rate, weight, and height measured, and an ECG performed. Baseline blood samples will be collected as per the standard of care pre-CABG and/or valve surgery.
CABG and/or replacement valve surgery: The patient will then undergo their planned CABG and/or replacement valve surgery as usual.
Blood Sampling: The patient will have hourly blood samples taken through the tubes inserted for their surgery for up to 14 hours to compare with the sensor readings. These samples will include 12 arterial lactate, 12 central venous lactate, and 12 venous troponin samples. Hourly measurements of the patient's blood pressure, heart rate, and respiratory rate will be taken, and any medication changes will be noted.
Sensor Removal: Up to 48 hours post-surgery, the sensors will be removed, and the patient's skin will be checked for any changes, like a rash. The patient will also have their blood pressure, heart rate, and respiratory rate measured, and an ECG performed. Any changes to the patient's medication will be noted.
Follow-Up: The study team will monitor the patient for up to 24 hours after the sensor is removed or until the patient is discharged from the hospital (whichever is earlier). The study team will note any medication changes, measure the patient's blood pressure, heart rate, and respiratory rate, and perform an ECG.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Investigational Lactate Device | Experimental | Device: Continuous Lactate Monitoring DeviceContinuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Able and willing to give informed consent
- ≥18 to ≤ 90 years old
- Successful surgery as defined by the below criteria (which will be recorded in the eCRF):
Key exclusion criteria (15 listed)
- Previous coronary artery bypass grafting
- Recent acute coronary syndrome (within 4 weeks of planned consent date)
- Heart failure with EF less than 35% (from TTE or CT from past 6 months - if both available lower value will be used).
- Chronic severe renal failure (estimated eGFR less than 30 mL/min/1.73m2 by the MDRD formula recorded at time of consent)
- Severe anaemia (Hb less than 10 recorded at time of consent)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous Lactate Monitoring DeviceContinuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device. | Device | Investigational Lactate Device |
Primary outcome
Continuous lactate sensor measurement compared venous and arterial blood gas lactate measurements.
Time frame: 14 hours
Correlation coefficients describing the strength of association between the electrical signal from the continuous interstitial fluid lactate measurements and laboratory lactate measurements. Evaluate the change in interstitial fluid lactate measurements via a surrogate output of change in current (nA; using an investigational device by Abbott Diabetes Care Ltd.) to local Radiometer ABL 90 venous and arterial blood gas lactate measurements measured hourly up to 12 samples within a 14-hour period post-elective CABG/valve replacement surgery.
Continuous lactate sensor measurement compared Troponin-T
Time frame: 14 hours
Correlation coefficients describing the strength of association between the electrical signal from the continuous interstitial fluid lactate measurements and venous laboratory measurements of high-sensitivity troponin-T. Evaluate the relationship between the current (nA) output of a continuous interstitial fluid lactate monitor (using an investigational device by Abbott Diabetes Care Ltd.) and venous laboratory measurements of high-sensitivity troponin-T measured hourly up to 12 samples within a 14-hour period post-elective CABG/valve replacement surgery.
4 secondary outcomes
Relationship between arterial and venous lactate measurements
Time frame: 14 hours
Relationship between arterial and venous lactate and venous troponin measurements
Time frame: 14 hours
Functionality of the device for up to 48 hours post-surgery.
Time frame: 48 hours
Evaluate safety of lactate sensor
Time frame: Up to 8 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Bypass
Not yet recruiting
Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine
Right Ventricular Function, Prone Position
Enrolling by invitation
Feasibility of Physical Prehabilitation for High-Risk Patients Undergoing Cardiac Surgery Via Sternotomy
Prehabilitation, Cardiac Surgery
Not yet recruiting
Fasciotomy and Predilation for Radial Artery Grafts in CABG
Coronary Artery Bypass, Radial Artery Grafts
Not yet recruiting
Bilateral Pecto-Intercostal Fascial Plane Block for Prevention of Chronic Poststernotomy Pain After CABG
Chronic Poststernotomy Pain
RecruitingObservational study
Prospective Study Protocol for Multiparametric PCCT Assessment of Early Ventricular Outcomes After CABG
Coronary Artery Bypass Grafting (CABG) Surgery, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Prof Anthony Mathur study chair
Queen Mary University of London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous Lactate Monitoring Device in people with Coronary Artery Bypass and Coronary Artery Bypass Graft, run by Queen Mary University of London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Continuous lactate sensor measurement compared venous and arterial blood gas lactate measurements. (time frame: 14 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.